Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 1
2009 2
2011 1
2013 1
2014 1
2015 4
2016 6
2017 7
2018 12
2019 10
2020 10
2021 14
2022 19
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean quan li gao (8 results)?
The Application of Nanobody in CAR-T Therapy.
Bao C, Gao Q, Li LL, Han L, Zhang B, Ding Y, Song Z, Zhang R, Zhang J, Wu XH. Bao C, et al. Among authors: gao q. Biomolecules. 2021 Feb 8;11(2):238. doi: 10.3390/biom11020238. Biomolecules. 2021. PMID: 33567640 Free PMC article. Review.
IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor.
Liu Y, Zhou N, Zhou L, Wang J, Zhou Y, Zhang T, Fang Y, Deng J, Gao Y, Liang X, Lv J, Wang Z, Xie J, Xue Y, Zhang H, Ma J, Tang K, Fang Y, Cheng F, Zhang C, Dong B, Zhao Y, Yuan P, Gao Q, Zhang H, Xiao-Feng Qin F, Huang B. Liu Y, et al. Among authors: gao q. Nat Immunol. 2021 Mar;22(3):358-369. doi: 10.1038/s41590-020-00850-9. Epub 2021 Jan 11. Nat Immunol. 2021. PMID: 33432230
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.
Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang L, Wang B, Sun G, Ji Y, Cao G, Liu H, Cui T, Li N, Qiu W, Li G, Hou X, Luo H, Xue L, Zhang Y, Yue W, Liu Z, Wang X, Gao S, Pan Y, Galais MP, Zaanan A, Ma Z, Li H, Wang Y, Shen L; ORIENT-15 study group. Lu Z, et al. BMJ. 2022 Apr 19;377:e068714. doi: 10.1136/bmj-2021-068714. BMJ. 2022. PMID: 35440464 Free PMC article. Clinical Trial.
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2).
Xu J, Li Y, Fan Q, Shu Y, Yang L, Cui T, Gu K, Tao M, Wang X, Cui C, Xu N, Xiao J, Gao Q, Liu Y, Zhang T, Bai Y, Li W, Zhang Y, Dai G, Ma D, Zhang J, Bai C, Huang Y, Liao W, Wu L, Chen X, Yang Y, Wang J, Ji S, Zhou H, Wang Y, Ma Z, Wang Y, Peng B, Sun J, Mancao C. Xu J, et al. Among authors: gao q. Nat Commun. 2022 Feb 14;13(1):857. doi: 10.1038/s41467-022-28408-3. Nat Commun. 2022. PMID: 35165274 Free PMC article. Clinical Trial.
Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations.
Wang J, Zhang B, Peng L, Liu X, Sun J, Su C, Wang H, Zhao Z, Si L, Duan J, Zhang H, Li M, Zhu B, Zhang L, Li J, Guo J, Luo R, Qiu W, Ye D, Chu Q, Cui J, Dong X, Fan Y, Gao Q, Guo Y, He Z, Li W, Lin G, Liu L, Liu Y, Qin H, Ren S, Ren X, Wang Y, Xue J, Yang Y, Yang Z, Yue L, Zhan X, Zhang J, Ma J, Qin S, Wang B. Wang J, et al. Among authors: gao q. Ther Adv Med Oncol. 2023 Jul 16;15:17588359231187205. doi: 10.1177/17588359231187205. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37484525 Free PMC article. Review.
88 results